Introduction
Homozygous deletions of the p16
INK4A

/p14
ARF genes on human chromosome 9p21 have been detected in 10 ± 60% of gliomas, depending on tumor stage and grade (Nishikawa et al., 1995; Nobori et al., 1994; Olopade et al., 1992) . They also have been reported in primary cancers of the lung (Nobori et al., 1994; Okami et al., 1997; Schmid et al., 1998) , bladder (Balazs et al., 1997; Orlow et al., 1995; Stadler and Olopade, 1996) , head and neck (Gonzalez et al., 1997; Matsuura et al., 1998; Waber et al., 1997) , as well as in acute T cell leukemias (Hatta et al., 1995; Hori et al., 1998; Yamada et al., 1997) , and mesotheliomas (Kratzke et al., 1995 region have been described in gliomas (Farrell et al., 1997; Marshall et al., 1997) , pituitary adenomas (Farrell et al., 1997) , lung cancers (Kim et al., 1997; Schmid et al., 1998; Wiest et al., 1997) , melanomas (Flores et al., 1996; Ruiz et al., 1998) , bladder cancers (Habuchi et al., 1995; Keen and Knowles, 1994) , and breast cancers . Hence, it is important to determine if there are other expressed genes on chromosome 9p21 that may be deleted in malignant cells.
The housekeeping gene methylthioadenosine phosphorylase (MTAP) resides approximately 100 kb telomeric of p16
INK4A
, and is often co-deleted with the tumor suppressor gene (Chen et al., 1997; Dreyling et al., 1998) . A large survey of DNAs extracted from paran-embedded samples of primary gliomas and lung cancers revealed a common breakpoint between MTAP exons 4 and 5 in several of these specimens. Because high quality mRNA could not be readily extracted from the formalin-®xed tumors, we searched for, and eventually found, a glioma cell line with the same deletion breakpoint. Analysis of this cell line by Northern and Western blotting suggested that it expressed an abnormal MTAP fusion product. The two new exons of the fusion gene subsequently were cloned, and mapped 25 and 28 kb centromeric to p15
INK4B
. A transcript corresponding to these exons was detected in normal adult and fetal cells, but was not found in malignant cell lines with 9p21 deletions including this region.
Results
Fine mapping
Deletion analyses of the MTAP gene were performed in DNAs extracted from 50 non-small cell lung cancers (NSCLC) and 36 gliomas. Recurrent breakpoints between exons 4 and 5 of the MTAP gene were detected in six of the NSCLC and in two of the gliomas, for a combined frequency of 9.3%. In 38% of these cases, the 9p21 deletion extended centromeric of . However, the DNA available from the slides was insucient for complete analysis.
In order to study in more detail the possible consequences of the MTAP exon 4/5 breakpoint, 16 glioma xenografts were ®nely mapped (Figure 1 ). Three xenograft lines revealed a MTAP 4/5 breakpoint, and all had been established from the same patient (#245).
MTAP expression
The expression of MTAP mRNA and protein was examined in gliomas #245, #270, #693 and #696 by reverse transcriptase-PCR (RT ± PCR) and by immunoblotting. The RT ± PCR results con®rmed the DNA deletion analysis. Primers corresponding to MTAP exons 1 ± 4 produced an amplicon of the same size as that found in normal cDNA and in cDNA from glioma #696, and were consistent with the MTAP cDNA sequence. In contrast, primers from exons 5 ± 8 yielded no signal in glioma #245 (Figure 2 ), but produced the expected 504 bp amplicon in the nondeleted xenograft tumor #696. Finally, immunoblotting of protein extracts from glioma #245 with a polyclonal chicken antibody against recombinant MTAP revealed several faint lower molecular weight bands, possibly representing proteolytic degradation products, which were not observed in normal extracts, nor in an extract prepared from a glioma xenograft (#693) with a complete homozygous deletion of the MTAP gene (data not shown).
Isolation of an MTAP fusion product
Since the expression of MTAP exons 1 ± 4 also could be shown using mRNA puri®ed by oligo-d(T) chromatography, it seemed likely that the transcript included a polyadenylation sequence, despite lacking the 3'-terminal exon of the MTAP gene. To identify the origin of this sequence, 3'-RACE was carried out, and the product was cloned and sequenced ( Figure 3) . The results revealed an in-frame fusion that added 476 bp and 27 amino acids to the truncated MTAP sequence. A fusion product-speci®c PCR con®rmed that xenografts #245, #245 USR, and #245 PR produced the same abnormal transcript. The full-length fusion sequence was deposited in the genbank (accession no. AF 109294).
Mapping the fusion gene
A survey of the GenBank for the new sequence revealed that it came from two separate regions of a recently sequenced cosmid, c86 (GenBank accession number AC000049). The 44 kb cosmid c86 also includes p15
INK4B exons 1 and 2, and p14 ARF exon 1b (Figure 4 ). The exon boundaries were predicted as INK4B and MTAP using gene speci®c primers and primers for STS (underlined numbers on the top). The original sample number is indicated on the left side. All tumors were established in nude mice. The ®rst ®ve xenografts were derived from childhood malignant gliomas, the others from adults. One hundred ng of total DNA were ampli®ed in each PCR reaction and PCR products were analysed on a 2% agarose gel stained with ethidium bromide. Black circles (*) represent wild type; open circles (*) indicate a homozygous deletion splice sites using the HSPL splice site prediction program (http://dot.imgen.bcm.tmc.edu:9331/gene-®n-der/gf.html) and are separated by a 3 kb intervening sequence. Accordingly, the two new sequences in the fusion gene were designated c86 
Expression of c86
fus exons 1 and 2
Transcripts containing both c86 fus exons 1 and 2 were detected by RT ± PCR in normal adult peripheral blood lymphocytes (PBL), in fetal brain, and in a representative malignant cell line (CCF-STTG1) without a chromosome 9p deletion ( Figure 5 ). In contrast, several dierent malignant cell lines with large 9p homozygous deletions (e.g., BLIN-1 in Figure 5 ) produced no RT ± PCR product. Using primers for MTAP exon 4 and c86 fus exon 1, fusion transcripts were not detected in any of eight malignant cell lines that were screened, including A549, MCF-7,MOLT-4, SW488, IM-9, RAJI, DU145 and T98G. To determine the size and level of expression of the normal c86 fus transcript, Northern blotting studies were carried out, using the ampli®ed product of the two exons as a probe ( Figure 6 ). A 1.5 kb transcript was observed in CCF-STTG1, and in normal PBL, but not in the Jurkat cell line with a large 9p21 deletion. Interestingly, MCF-7 and T98G showed very faint 1.5 kb bands. These cell lines have p16
INK4A deletions but are not deleted in the p15
INK4B
-c86 fus area. One possible explanation is that the expression of the transcript is down-regulated by mechanisms like mutation or hypermethylation. The existence of another exon telomeric of p15 INK4B is rather unlikely since the size of the very faint band in MCF-7 and T98G is indistinguishable from the one observed in CCF-STTG1 and normal lymphocytes. As estimated by densitometry, the c86 fus transcript was present at less than 5% of the levels of the housekeeping gene GAPDH.
We used a human RNA master blot to analyse the expression pattern of c86 fus . It is expressed in all tissues of the adult whereas the highest levels were found in heart, brain and pituitary gland. In contrast, c86 fus was not found in fetal brain and it was expressed at very low levels in all fetal tissues tested ( Figure 7 ). In addition, we hybridized the same blots with a p16 INK4A speci®c probe. Interestingly, there was a signi®cant correlation between c86 fus and p16
INK4A
expression levels, especially with respect to the dierences observed in adult and fetal tissues. A third hybridization with a GAPDH-speci®c probe was done as a control (data not shown). These results suggest that c86 fus is regulated in the same way as p16
.
Discussion
The results of these experiments show that both gliomas and non-small cell lung cancers with chromosome 9p21 homozygous deletions may have a breakpoint between exons 4 and 5 of the MTAP gene. This anomaly can lead to the expression of a fusion sequence joining the four remaining exons to two exons of a new gene located approximately 25 and 28 kb centromeric of p15
INK4B
. In normal cells, the two exons (designated c86 fus exons 1 and 2) formed part of a 1.5 kb transcript. This transcript was not found in malignant cells with 9p21 deletions in this region. In addition, we were unable to amplify the fusion transcript in eight dierent malignant cell lines although some of them contain the MTAP exons 4/5 breakpoint and/or a breakpoint centromeric of p16
INK4A
. This could be explained by the existence of several dierent breakpoint clusters within the intronic region between MTAP exons 4/5. A very short half-life or an unstable fusion mRNA might be other possibilities. However, the cloning of the exact genomic breakpoints is mandatory to clarify this question. Figure 1 . One mg of total RNA was transcribed into cDNA using random primers and 2 ml of the product were used for PCR. PCR products were electrophoresed on a 2% agarose gel containing 0.4 mg/ml ethidum bromide. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MTAP164, primers amplify exactly MTAP exon 1 to exon 4; MTAP568, primers amplify exactly from MTAP exons 5 ± 8
Oncogene A MTAP fusion sequence identifies a new transcript M Schmid et al Deletion breakpoints between exons 4 and 5 of the MTAP gene previously have been found in some acute T cell leukemias (Batova et al., 1996) . One mechanism for disruption of the p15
INK4A /MTAP region in T cell leukemias may be the action of an illegitimate V(D)J recombinase (Cayuela et al., 1997) . However, it seems unlikely that the recombinase would function in gliomas and non-small cell lung cancers. It is conceivable that malignant cells with this breakpoint have a selective survival advantage, due to the creation of one or more fusion genes with altered function or stability. To test this hypothesis will require a detailed study of the eects of the expressed fusion sequence on the in vivo growth and invasiveness of malignant cells.
A database comparison of the new amino acid sequence contributed by the fusion gene did not reveal any signi®cant homologies indicative of its function.
The new sequences of the MTAP fusion gene came from two separate regions of the recently sequenced cosmid c86 (Figure 4) . Reverse transcriptase PCR with exon-speci®c primers indicate that they form two exons of a transcript found in both quiescent normal lymphocytes and in various proliferating cells. Since the two identi®ed exons are separated by 3 kb, the ampli®ed product could not have come from contaminating DNA. Moreover, hybridization of oligo-d(T) puri®ed mRNA with the ampli®ed sequence revealed a 1.5 kb band, which was present only in cells without , and exon 1b of p14 ARF . However, preliminary RT ± PCR studies with primer pairs corresponding to these ESTs, and to either c86 fus exons 1 and 2, did not produce an ampli®ed product. Thus it is possible that the additional exons of the new gene are not included in the c86 cosmid.
By using a multiple tissue Northern blot, we could demonstrate that the expression pro®les of c86 fus and p16
INK4A are very similar, especially with respect to the fact that both are expressed in adult tissues but at very low or no levels in fetal tissues. This could imply that c86fus plays (like p16
) also a role in sensecence and dierentiation. Since p16
INK4A is regulated by hypermethylation, it might be possible that this epigenetic fus exon 1 and c86 fus exon 2 are about 25 and 28 kb centromeric of p15 INK4B exon 1 (grey boxes). A head-to-head orientation between these two transcripts is assumed. The fusion product formation between c86 fus exon 1, c86 fus exon 2, and MTAP exons 1 ± 4 (dashed boxes) is shown Figure 5 Transcripts containing c86 fus exon 1 and c86 fus exon 2 were detected by RT ± PCR. First-strand cDNA synthesis was performed as indicated in Materials and methods. PCR ampli®cation was performed using primers c86SE and c86AS primers in c86 fus exon 1 or c86 fus exon 2 respectively. The transcript was found in CCF-STTG1 cells, an astrocytoma cell line that is not deleted at the chromosome 9p21 locus, in normal periperal lymphocytes, fetal brain (Invitrogene, Carlsbad, CA, USA) but not in the lymphoblastoid cell line BLIN-1, which has a large 9p21 deletion Figure 6 Northern blot analysis of the c86 fus transcript. Equal amounts of total RNA (20 mg) were loaded in each lane and separated on a 1.2% formaldehyde-containing agarose gel, blotted onto a positively-charged nylon membrane, and probed with the 32 P-dCTP radiolabeled 222 bp RT ± PCR fragment described in Figure 5 . A clear 1.5 kb band could be detected in CCF-STTG1 and normal lymphocytes, but not in RNA from the Jurkat cell line with a 9p21 deletion. MCF-7 and T98G cells showed a much fainter 1.5 kb band despite the fact that they are not deleted at the c86 fus locus, suggesting the existence of a underlying cis-acting regulatory mechanism In this regard, there is accumulating evidence for one or more tumor suppressor genes on chromosome 9p outside of the p15
INK4A locus. An et al. (1996) reported that the most common region of allele loss on 9p21-22 in sporadic breast cancer was centromeric of the p16 INK4A locus. In a study of 44 gliomas, Li et al. (1995) found a frequent loss of heterozygosity on chromosome 9p, but a low incidence of p16
INK4A mutations, and concluded that there must be another tumor suppressor gene in the vicinity of p16 INK4A and p15
INK4B
. Moulton et al. (1995) analysed 27 gliomas, and also suggested that there may be one or more additional tumor suppressor genes on 9p21. Marshall et al. (1997) mapped a deleted region in neuroblastoma centromeric of the p16 INK4A gene. Both Puig et al. (1995) and Ruiz et al. (1998) , two genes that share 2 exons, or (3) just be a non-translated mRNA with an unknown function. Since nobody knows how the expression between the p14 ARF and p16 INK4A transcript is regulated, possibly number two might explain this. In future studies, it will be important to determine the frequency of expression of transcripts hybridizing to the c86 fus probe in primary tumors with loss of heterozygosity at chromosome 9p, but without detectable abnormalities of p16 INK4A . Our initial experiments indicate that the expression levels of the 1.5 kb transcript are reduced in malignant cells with isolated deletions of p14 ARF /p16
INK4A
, suggesting the existence of cis-acting regulatory mechanisms. Additional studies of the structure and function of this gene should reveal its potential role in the evaluation of cancers with 9p abnormalities.
Materials and methods
Tumor samples
Formalin-®xed, paran-embedded lung cancers and gliomas were obtained and processed as described previously (Perry et al., 1997; Schmid et al., 1998) . Brie¯y, the tumor-rich parts of each specimen were scratched o, deparanized in octane, washed in ethanol and dried. Sixteen xenografts were established at Duke University (Durham, NC) both from childhood (n=5) and adult (n=11) primary gliomas, and were propagated in nude mice to a diameter of 2 cm. Excised tumors were stored at 7708C until analysed.
Deletion analysis
DNA was isolated using a Qiagen Tissue Kit, followed by incubation with RNase A. The DNA was stored at 7208C until analysed. A total of 50 ng of DNA from each sample was used for PCR ampli®cation. Primers for MTAP, 3.21, 2F, 54F, p16 INK4A and p15 INK4B are shown in Table 1 . The recently cloned pseudogene of MTAP (CMTAP), localized to chromosome 3p28, served as a reference gene (Tran et al., 1997) . All primer pairs were designed to amplify PCR products of similar length between 197 ± 250 bp.
Zero to 100 ng of control DNA (extracted from human paran-embedded placenta tissue) were ampli®ed in each experiment to show the linearity of the PCR reaction and to provide a standard for comparison of ampli®ed tumor sample DNA to normal DNA products. PCR was performed in a total of 50 ml containing normal or sample DNA, 2.0 mM MgCl 2 , 2.0 ml digoxigenin PCR Mix (200 mM each of dATP, dCTP, and dGTP, 190 mM dTTP and 10 mM digoxigenindUTP) (Boehringer Mannheim, Indianapolis, IN, USA), 7.5 ± 15 pmol of each primer, and 5 U AmpliTaq Gold DNA Polymerase (Perkin Elmer, Branchburg, NJ, USA) in the reaction buer provided by the supplier. Due to a very high GC content of p16 INK4A exon 1a, ampli®cation was performed in a reaction mixture containing 5% dimethylsulf- Figure 7 Correlation between the expression patterns of c86 fus and p16 INK4A in 50 dierent human tissues. Speci®c probes for the two genes were used for hybridization to a commercially available RNA master blot 1 membrane as described in Materials and methods oxide (DMSO). Samples were ampli®ed through 27 cycles (fresh tissue) or 29 ± 33 cycles (paran-embedded tissues) in a Perkin Elmer thermal cycler using the following parameters: initial denaturation at 948C for 5 min, then 27 (29 ± 33, respectively) cycles of 948C denaturation for 1 min, annealing at 598C for 1 min (648C in case of p16 INK4A exon 1a), polymerization at 728C for 1 min and a ®nal extension step at 728C for 7 min. Ten ml of the PCR reactions were analysed by electrophoresis at 100 V for 45 min in a 2% agarose gel in Tris-borate buer containing 2 mM EDTA and 0.4 mg/ml ethidium bromide. Gels were photographed, scanned, and the intensities of the bands were compared.
Western blot analysis
Xenograft tumors were dissected using a razor blade. The sections were crushed in microfuge tubes containing 500 ml of RIPA-M buer (50 mM NaCl, 50 mM Tris pH 7.4, 0.5% NP-40, 1 mM EGTA, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM PMSF). Samples were further disrupted by passing several times through an 18G needle, then a 22G needle, a 27G, and incubated at 48C overnight. Then, samples were spun down at 12 000 g for 10 min, and the protein in the supernatant was quanti®ed with a Pierce Coomassie Plus Protein Assay Reagent (Rockford, IL, USA). After boiling in sample buer for 5 min, equal amounts of 50 mg were separated by SDSpolyacrylamide gel electrophoresis, transferred to PVDF membranes, blocked overnight with 1% casein-blocking solution, and probed for 1 h at 208C with a polyclonal chicken antibody generated against recombinant human MTAP, followed by a 30 min incubation with a secondary alkaline phosphatase-labeled goad anti-chicken antibody. Bound antibody was detected by chemiluminescence (CSPD, Boehringer Mannheim, Indianapolis, IN, USA).
Reverse Transcriptase ± PCR (RT ± PCR)
Total RNA was extracted from tumor tissues using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). About 25 mg of tissue were homogenized by aspirating several times with a 1 cc syringe through a 22G needle in lysis buer. RNA was eluted from spin columns in 30 ml DEPC-treated water. One mg of RNA was transcribed into single-stranded cDNA using a ®rst-strand cDNA synthesis kit (Gibco-BRL, Gaithersburg, MD, USA) and oligo-d(T) primers.
RT ± PCR was carried out in a total volume of 50 ml including 2 ml cDNA 2.0 mM MgCl 2 , 200 mM dNTPs (Sigma, St. Louis, MO, USA), 7.5 pmol of each primer, and 5 U AmpliTaq Gold DNA Polymerase (Perkin Elmer, Branchburg, NJ, USA) in the reaction buer provided by the supplier. PCR conditions were as follows: Initial 5 min, 948C, 35 cycles of 948C, 30 s, 588C, 30 s, 728C 1 min, and a ®nal extension of 7 min at 728C. Primers for GAPDH served as a positive control (Table 1) . PCR products were separated by electrophoresis on a 2% agarose gel.
3' RACE ± PCR
Total RNA was isolated as described above. One mg of RNA was transcribed into single stranded cDNA using an oligod(T)-adaptor primer (Integrated DNA Technologies, Coralville, IO, USA) at 508C for 1 h. 3' RACE ± PCR was performed as semi-nested PCR using the same adaptor primer in both PCR-reactions. The gene-speci®c primer (GSP) for the ®rst PCR was located in MTAP exon 1. The GSP in the second, semi-nested PCR reaction came from MTAP exon 4 (5'-AGG CGA ACA TCT GGG CTT TGA-'3). Long-TaqPolymerase (Stratagene, La Jolla, CA, USA) was used for ampli®cation, and conditions in both PCR-reactions were as follows: Initial denaturation at 948C, 10 min, 35 cycles consisting of 948C for 30 s, annealing at 608C for 30 s, extension at 728C for 4 min, and one ®nal cycle for 20 min at 728C. PCR products were analysed on a 1% agarose gel, puri®ed using the Qiaex II gel extraction kit (Qiagen), and subcloned into PCRscript 1 blunt-end cloning vector (Stratagene). Sequence analysis was performed on 15 dierent clones using an automated sequencer (ABIPRISM 1 , Perkin-Elmer Applied Biotechnologies).
Northern blotting
Twenty mg of total RNA on a 1.2% formaldehyde-containing agarose gel were electrophoresed at 40 ± 50 V over 4 h. RNA was then transferred overnight to a positively charged nylon membrane and nucleic acids were UV-cross-linked using the Stralinker transilluminator (Stratagene, La Jolla, CA, USA). The membrane was prehybridized for 2 h at 688C in ExpressHyb hybridization buer (Clontech, Palo Alto, CA, USA) containing 10 mg/ml salmon sperm DNA and 1.5 mg/ ml C o t-DNA (Boehringer-Mannheim). The probe used for hybridization was generated by nested-RT ± PCR using two primer pairs amplifying a 222 bp fragment of the two new exons on cosmid c86 (see Figure 4) . After nick-translation radiolabeling with 32 P-dCTP, 100 ng (spec. act.456 10 8 c.p.m./mg DNA) of the probe was added to the prehybridization solution and incubated at 688C overnight on a shaker platform. The membrane was washed twice with 26SSC+1% SDS and twice with 0.16SSC+0.5% SDS for 15 min at 608C and 428C, respectively. Autoradiography was performed by exposure to a Kodak X-ray ®lm at 7708 for 18 h.
The 222 bp product generated by RT ± PCR using sense (c86SE, 5'-TAT TTG CCA CGA CAT TTC A-3') and antisense (c86AS, 5'-AAA AAT CAT CTT CAC ATC C-3') primers in exons c86 fus exon 1 and c86 fus exon 2, respectively, was used to probe a RNA Master Blot membrane (Clontech, Palo Alto, CA, USA). In addition, the same membrane was subsequently hybridized with a p16
INK4A speci®c probe as well as with a GAPDH-speci®c probe (control). All probes were labeled with 32 P-dCTP, 100 ng (spec. act.45610 8 c.p.m./mg DNA) using the random prime labeling method (Statagene, La Jolla, CA, USA). Hybridization and washes were performed according to the manufacturer's guidelines followed by a 24 h exposure to a Kodak X-ray ®lm at 7708C.
